A Phase 2a, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of AL-3778 in Combination With Peginterferon Alpha-2a in Treatment Naïve Chronic Hepatitis B Subjects Who Are HBeAg-positive

Trial Profile

A Phase 2a, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of AL-3778 in Combination With Peginterferon Alpha-2a in Treatment Naïve Chronic Hepatitis B Subjects Who Are HBeAg-positive

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2017

At a glance

  • Drugs NVR 3778 (Primary) ; Peginterferon alfa-2a
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Alios BioPharma
  • Most Recent Events

    • 13 Oct 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 15 Aug 2017 Planned End Date changed from 30 Dec 2018 to 15 Feb 2019.
    • 15 Aug 2017 Planned primary completion date changed from 30 Dec 2018 to 15 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top